Coronavirus disease 2019-associated rapidly progressive organizing pneumonia with fibrotic feature: Two case reports : Medicine

Journal Logo

Research Article: Clinical Case Report

Coronavirus disease 2019-associated rapidly progressive organizing pneumonia with fibrotic feature

Two case reports

Okamori, Satoshi MDa; Lee, Ho MDa; Kondo, Yasushi MD, PhDb; Akiyama, Yuto MDa; Kabata, Hiroki MD, PhDa,∗; Kaneko, Yuko MD, PhDb; Ishii, Makoto MD, PhDa; Hasegawa, Naoki MD, PhDc; Fukunaga, Koichi MD, PhDa

Editor(s): Saranathan., Maya

Author Information
doi: 10.1097/MD.0000000000021804
  • Open


1 Introduction

The novel coronavirus disease 2019 (COVID-19) is spreading worldwide. Although pneumonia is 1 of the most important clinical characteristics of the disease,[1] the detailed features and its appropriate treatment are not yet clear. Chest computed tomography (CT) is a useful diagnostic tool for COVID-19. Although multifocal patchy ground-glass opacity (GGO) and consolidations are common, the CT findings of COVID-19 pneumonia are diverse and change over disease course.[2] Some patients have been reported to have findings suggestive of organizing pneumonia (OP) such as consolidation or reversed halo sign.[2] However, there are few case reports detailing the clinical and treatment course of OP caused by COVID-19.

Herein, we describe 2 cases of COVID-19-associated OP. Notably, both patients had rapid reduction in lung volume and respiratory failure accompanied by findings of pulmonary fibrosis on chest CT. Antiviral drugs had no apparent effect on disease progression, and both cases were successfully treated with systemic corticosteroid therapy.

2 Case presentation

2.1 Case 1

A 60-year-old man presented with a 7-day history of fever and cough. He had a medical history of gastroesophageal reflux disease and dyslipidemia. On admission, he presented with a pulse of 85 bpm, temperature of 38.5 °C, blood pressure of 132/88 mmHg, and oxygen saturation of 96% when breathing air. Laboratory data revealed elevated serum LDH (351 U/L), AST (149 U/L), ALT (82 U/L), and C-reactive protein (CRP) (8.23 mg/dL). Lymphopenia and coagulopathy were not observed. Chest X-ray and CT scan revealed patchy GGO predominantly distributed in the subpleural regions of the lungs (Fig. 1A–C). Real-time reverse transcription polymerase chain reaction (RT-PCR)-based tests for severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) virus were positive. The patient was diagnosed with COVID-19 pneumonia and treated with levofloxacin, ciclesonide, and favipiravir.

Figure 1:
Chest imaging of Case 1. (A) Chest X-ray on admission. A slight ground-glass opacity (GGO) was observed in the right lung. (B, C) Chest computed tomography (CT) on admission revealed bilateral patchy GGO that was predominantly distributed throughout subpleural areas. (D) Chest X-ray on day 6 post hospital admission (taken immediately before corticosteroid administration) revealed consolidations and marked lung volume loss. (E, F) Chest CT on day 6. Consolidations developed bilaterally, some with band-like shapes. A central GGO surrounded by ring-shaped areas of consolidation (reversed halo sign) was observed (black arrow). Some GGOs were accompanied by traction bronchiectasis (white arrow). The volume of both lower lobes was decreased. (G) Chest X-ray and (H, I) Chest CT on day 23 revealed improvement of lung infiltration and recovery of lung volume. CT = computed tomography.

On day 6 post hospital admission, he continued to have a fever and required 3 L/min oxygen via nasal canula to maintain an oxygen saturation of >90%. Serum CRP was 21.64 mg/dL and LDH was 541 U/L. Lymphopenia (806 cells/μL) and elevated serum ferritin (2,110 ng/mL) were observed. The patient had no signs of connective tissue disease (CTD), such as joint pain/swelling, proximal muscle weakness, and cutaneous rash. Serum creatinine kinase was not elevated, and anti-nuclear antibody tests were repeatedly negative. His chest X-ray revealed lung consolidation and marked lung volume reduction (Fig. 1 D). Further, his chest CT scan revealed consolidation, accompanied with reversed halo sign, traction bronchiectasis, and volume loss of the lower lobes (Fig. 1E, F). The patient was administered 1,000 mg methylprednisolone daily for 3 days, followed by a daily dose of 80 mg/day (1 mg/kg) prednisolone. His fever and chest X-ray improved rapidly, and his respiratory condition also improved (Fig. 2). Viral RT-PCR results were negative on day 16. Prednisolone was tapered without disease recurrence and the treatment ended on day 18. Chest imaging on day 23 revealed lung volume and infiltrate improvement (Fig. 1 G–I), and the patient was discharged on day 24.

Figure 2:
Clinical course of Case 1. Systemic corticosteroid treatment was initiated on day 6 post hospital admission. Subsequently, the patient's fever, respiratory condition, and laboratory data improved. mPSL = methylprednisolone, BT = body temperature, CRP = C-reactive protein.

2.2 Case 2

A 61-year-old woman presented with a 7-day history of fever, headache, and dysgeusia. She had a medical history of bronchial asthma, hypothyroidism, and hypertension. On admission, she had a pulse of 97 bpm, temperature of 38.4 °C, blood pressure of 141/91 mmHg, and oxygen saturation of 96% when breathing air. Laboratory data revealed lymphopenia (510 cells/μL) and elevated serum CRP (9.93 mg/dL) and ferritin (269 ng/mL) levels. Chest X-ray and CT showed slight GGO (Fig. 3 A–C). She was diagnosed with COVID-19 after receiving a positive test result via real-time RT-PCR for SARS-CoV-2. She was treated with ceftriaxone, azithromycin, favipiravir and hydroxychloroquine.

Figure 3:
Chest imaging of Case 2. (A) Chest X-ray on admission. A slight ground-glass opacity (GGO) was observed in the right lower lung field. (B, C) Chest computed tomography (CT) on admission showed bilateral faint GGO. (D) Chest X-ray on day 6 post hospital admission (immediately before corticosteroid administration) showed bilateral GGO. Lung volume was markedly decreased. E, F: Chest CT on day 6. Consolidations developed bilaterally, some of which producing band-like shapes, and were distributed in subpleural or peri-bronchial regions. Traction bronchiectasis was observed (white arrow). A (G) Chest X-ray and (H, I) chest CT on day 17 revealed improvement of lung infiltrates and the recovery of lung volume. CT = computed tomography.

On day 6 post hospital admission, the patient's fever continued, she developed dyspnea and fatigue, and required 1 L/min oxygen via the nasal canula to maintain >90% oxygen saturation. Serum levels of CRP remained high (7.32 mg/dL), and lymphopenia (328/μL) and serum ferritin level (414 ng/mL) worsened. She had no signs of CTD. Serum creatinine kinase was not elevated, and both anti-aminoacyl-tRNA synthetase and an anti-melanoma differentiation associated gene 5 antibodies were negative. A chest X-ray revealed bilateral GGO and marked lung volume reduction (Fig. 3D). CT scan revealed bilateral consolidations, some of which showed band-like shapes and distributed in subpleural or peri-bronchial region. Traction bronchiectasis were also observed (Fig. 3E, F). We performed real-time RT-PCR for SARS-CoV-2 again and found an increased Ct value, which suggested decreased viral load. She was administered prednisolone 50 mg/day (0.75 mg/kg). Her fever and the level of serum CRP improved rapidly, followed by an improvement in the respiratory condition (Fig. 4). Chest imaging on day 17 revealed infiltrate and lung volume improvements (Fig. 3G–I), and a viral real-time RT-PCR test performed on the same day was negative. Prednisolone was tapered until the treatment concluded on day 18 without disease recurrence, and the patient was discharged on day 20.

Figure 4:
Clinical Course of Case 2. After the systemic corticosteroid treatment was initiated on day 6 post hospital admission, the patient's fever, respiratory condition, and laboratory data improved. BT = body temperature, CRP = C-reactive protein.

3 Discussion

Here, we present two cases of rapidly progressive COVID-19 pneumonia. Chest imaging revealed the development of OP with fibrotic features and reduced lung volume. Notably, these findings improved with systemic corticosteroid treatment.

Several previous studies reported the development of OP during the clinical course of COVID-19.[3–5] Copin et al confirmed the OP findings using autopsy lungs of patients who died from COVID-19.[6] Typically, patients with OP display subacute disease over several weeks without apparent lung fibrosis.[7] However, some patients with OP present with rapid disease progression and lung fibrosis, which is called “fibrosing variant of OP”.[8–10] This degree of rapidly progressive and fibrotic OP is commonly observed in poly/dermatomyositis, especially in patients presenting with clinically amyopathic dermatomyositis associated with the anti- melanoma differentiation associated gene 5 antibody.[11] However, neither of the case presented showed symptoms, physical findings, or serum antibodies suggestive of CTD, including myositis. Hence, our case report suggests that COVID-19 causes rapidly progressive and fibrotic OP.

The benefits and drawbacks associated with systemic corticosteroid treatment for COVID-19 are a subject of debate.[12–14] Corticosteroids may control the “cytokine storm” frequently observed in COVID-19 patients,[15,16] and a retrospective cohort study reported that treatment with methylprednisolone decreased the risk of death among COVID-19 patients with acute respiratory distress syndrome (HR 0.38, 95% CI 0.20-0.72).[17] However, previous studies of viral infection, such as SARS, Middle East Respiratory Syndrome and Influenza virus pneumonia reported that systemic corticosteroid treatment was associated with unfavorable outcomes such as delayed virus clearance, increased incidence of hospital-acquired pneumonia, and increased mortality.[18–20] Likewise, recent systematic review and meta-analysis showed that the use of corticosteroids may increase mortality of severe COVID-19 patients (HR 2.30, 95% CI 1.00 to 5.29) although the calculated effect size was based on only two observational studies and thus the quality of evidence was low.[21] Several investigators have argued that that the timing of administration, and dosage of corticosteroid are important to adequately control the cytokine storm and prevent disease progression in COVID-19 patients.[16,22] In our cases, we repeatedly performed real-time RT-PCR for SARS-CoV-2 and found that viral load was decreased when OP findings appeared. Therefore, we administered corticosteroid to prevent further deterioration of respiratory failure, and patients improved rapidly without any unfavorable effects.

Our report has several limitations. First, this is only a report of a small number of cases at 1 institution. It is still unclear whether these rapidly progressive and fibrotic cases are subtypes of COVID-19-associated OP. Further cases with similar presentations are needed. Second, although the 2 cases presented were successfully treated with corticosteroid therapy, it does not prove the efficacy of corticosteroid against COVID-19. Until the results of ongoing randomized controlled trials are available,[23,24] we should carefully examine the indication of systemic corticosteroid according to each patient's situation.

4 Conclusion

Here, we reported 2 cases of COVID-19-associated OP, which presented with rapidly progressive respiratory failure and fibrotic changes on chest CT scan. For both cases, treatment with systemic corticosteroid rapidly resolved respiratory distress, and reversed lung fibrotic changes. Our findings suggest that physicians should carefully monitor patients with COVID-19 to prevent disease progression. Further investigation is needed to clarify the clinical characteristics of COVID-19-associated OP and confirm the potential benefit of corticosteroid treatment in COVID-19.


We would like to thank all the members of the Keio COVID-19 Lifesaving Team, the Keio Donner Project Team, and the staff who supported us at the Keio University Hospital.

Author contributions

Conceptualization: Satoshi Okamori, Hiroki Kabata.

Diagnosis and treatment: Ho Lee, Yasushi Kondo, Yuto Akiyama, Hiroki Kabata.

Writing – original draft: Satoshi Okamori, Ho Lee.

Writing – review and editing: Hiroki Kabata, Yuko Kaneko, Makoto Ishii, Naoki Hasegawa, Koichi Fukunaga.


[1]. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 2020;Feb 24. doi: 10.1001/jama.2020.2648. Online ahead of print.
[2]. Yang Q, Liu Q, Xu H, et al. Imaging of coronavirus disease 2019: a Chinese expert consensus statement. Eur J Radiol 2020;127:109008.
[3]. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging 2020;101:2638.
[4]. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020;200642.
[5]. Wu Y, Xie Y-l, Wang X. Longitudinal CT findings in COVID-19 Pneumonia: case presenting organizing pneumonia pattern. Radiology 2020;2:e200031.
[6]. Copin MC, Parmentier E, Duburcq T, et al. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med 2020;13. Apr 23.
[7]. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:73348.
[8]. Baque-Juston M, Pellegrin A, Leroy S, et al. Organizing pneumonia: what is it? A conceptual approach and pictorial review. Diagn Interv Imaging 2014;95:7717.
[9]. Roberton BJ, Hansell DM. Organizing pneumonia: a kaleidoscope of concepts and morphologies. Eur Radiol 2011;21:224454.
[10]. Beardsley B, Rassl D. Fibrosing organising pneumonia. J Clin Pathol 2013;66:87581.
[11]. Hoa S, Troyanov Y, Fritzler MJ, et al. Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review. Scand J Rheumatol 2018;47:21024.
[12]. National Institute of Health. COVID-19 Treatment Guidelines. Considerations for Certain Concomitant Medications in Patients with COVID-19. 2020;Available at: Published 2020. Updated April 21, 2020. Accessed May 20.
[13]. XXX, Wilson K, Chotirmall S, Bai C, et al. COVID-19: Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society-led International Task Force. 2020;Available at: Published 2020. Accessed May 20.
[14]. Alhazzani W, Moller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically Ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med 2020;46:85487.
[15]. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:26209.
[16]. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 2020;80:60713.
[17]. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:11.
[18]. Lansbury L, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2019;2:CD010406.
[19]. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004;31:3049.
[20]. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically Ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018;197:75767.
[21]. Ye Z, Wang Y, Colunga-Lozano LE, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ 2020;192:E75667.
[22]. Yang SS, Lipes J. Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series. Can J Anaesth 2020;13. May 11.
[23]. Glucocorticoid therapy for COVID-19 critically Ill patients with severe acute respiratory failure. Available at: Accessed May 20, 2020.
[24]. Efficacy and Safety of Corticosteroids in COVID-19. Available at: Accessed May 20, 2020.

coronavirus disease 2019; organizing pneumonia; corticosteroids

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.